SCHEMBL7184511

SCHEMBL7184511

COc1cc(OC)c(C(=O)P(=O)(C(=S)c2ccccc2)c2c(C)cccc2Cl)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
TAS1R2 Q8TE23 1/20 0.37
TOP1 P11387 1/20 0.36
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 6/20 0.35
MEN1 O00255 4/20 0.35
POLB P06746 1/20 0.35
PTGS2 P35354 1/20 0.35
DRD4 P21917 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
ATM Q13315 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187974 0.91 FABP4 (0.38) TAS1R3TAS1R1TAS1R2ALDH1A1POLB
SCHEMBL7180570 0.90 ABCG2 (0.41) ABCG2TAS1R3TAS1R1TAS1R2TOP1
SCHEMBL7189054 0.88 FABP4 (0.38) ALDH1A1POLBNPC1RAB9AHTT
SCHEMBL7180598 0.84 MAPT (0.36) ALDH1A1KMT2APOLBNPC1RAB9A
SCHEMBL7188241 0.84 FABP3 (0.37) ALDH1A1POLBNPC1RAB9AHTT
SCHEMBL7175915 0.83 TYK2 (0.39) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL7186800 0.82 LMNA (0.40) ALDH1A1KMT2AMEN1RAB9AHTT
SCHEMBL7184519 0.82 ABCG2 (0.40) ABCG2TOP1ALDH1A1KMT2AMEN1
SCHEMBL7175979 0.81 ABCG2 (0.42) ABCG2TAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL7182181 0.81 ATM (0.42) TAS1R3TAS1R1TAS1R2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ABCG2 4323/4885TAS1R3 3176/4885TAS1R1 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.